New combo aims to stop leukemia from coming back
NCT ID NCT07463768
First seen Mar 13, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from returning in patients over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills daily until the disease progresses or side effects become too much. The main goal is to see how many remain relapse-free after two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH côte Basque
Bayonne, 64109, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH de Perpignan
Perpignan, 66046, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHRU Nancy
Vandœuvre-lès-Nancy, 54500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Angers
Angers, 49933, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Besançon
Besançon, 25030, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Grenoble
Grenoble, 38043, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Henri Mondor
Créteil, 94000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Limoges
Limoges, 87000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nantes
Nantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nîmes - Institut de Cancérologie du Gard
Nîmes, 30029, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de TOULOUSE - IUCT ONCOPOLE
Toulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Henri Becquerel
Rouen, 76038, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chru Bretonneau
Tours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chru de Lille - Hopital Claude Huriez
Lille, 59037, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Rennes - Hopital Pontchaillou
Rennes, 35033, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gustave Roussy
Villejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital d'Instruction des Armées Percy
Clamart, 92140, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Haut-Lévêque
Pessac, 33604, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Lyon-Sud
Pierre-Bénite, 69310, France
-
Hôpital Saint Louis
Paris, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.